But the second point I would make is to the extent that some people are concerned that the time that Pharmac often takes to make a decision can be very lengthy, that is precisely the objective of the review that we've commissioned in relation to Pharmac, which is to look at the timeliness and agility of its decision making. I think there is some justified criticism of Pharmac not making decisions in a timely enough way when new technologies are available, and we want to see improvement in that regard. But let's wait to see what the outcome of that review is before we get too concerned about them.